CTKBHIGH SIGNALFINANCIAL10-K

CTKB's net income plummeted over 1000% to -$66.5M despite 18% revenue growth, while the company dramatically increased share buybacks by 274% and burned through operating cash flow.

The massive deterioration in profitability despite strong revenue growth suggests serious operational inefficiencies or one-time charges that management may be masking through aggressive share buybacks. The shift from positive to negative operating cash flow while simultaneously quadrupling buyback spending raises concerns about capital allocation discipline and potential liquidity pressure ahead.

Comparing 2026-02-26 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

CTKB shows a troubling disconnect between top-line growth (revenue up 18% to $193M) and profitability, with net losses exploding over 1000% and operating cash flow turning deeply negative. The company's response was to dramatically increase share buybacks by 274% to $80.8M while liabilities grew 15% and equity declined 14%, suggesting management may be prioritizing financial engineering over addressing underlying operational challenges. This combination of deteriorating cash generation, aggressive capital returns, and weakening balance sheet metrics signals potential financial stress despite the revenue growth.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-1005.3%
-$6.0M→-$66.5M

Net income declined 1005.3% — review whether driven by operations, interest costs, or non-recurring items.

Share Buybacks
Cash Flow
+273.9%
$21.6M→$80.8M

Share repurchases increased 273.9% — management returning capital, signals confidence in intrinsic value.

Operating Cash Flow
Cash Flow
-118.5%
$25.4M→-$4.7M

Operating cash flow fell 118.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-96.8%
-$20.5M→-$40.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+17.7%
$164.0M→$193.0M

Revenue growing 17.7% — solid top-line momentum, watch margins for quality of growth.

Total Liabilities
Balance Sheet
+15.5%
$103.8M→$119.8M

Liabilities increased 15.5% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+15%
$67.7M→$77.8M

Current liabilities rose 15% — increased short-term obligations, watch current ratio.

Stockholders Equity
Balance Sheet
-13.6%
$395.7M→$341.7M

Equity decreased 13.6% — buybacks or losses reducing book value, monitor solvency ratios.

Inventory
Balance Sheet
+10.3%
$43.9M→$48.4M

Inventory built 10.3% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-28
ADDED
commercial launch in mid-2017, we have sold and deployed our instruments to customers around the world, including pharmaceutical companies, biopharma companies, academic research centers, and contract research organizations ( CROs ).
Flow Cytometry and Imaging (FCI) Business In addition to our FSP product portfolio, pursuant to an acquisition in February 2023, we offer conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brands, which provide insights into all facets of cellular phenotypes and morphology.
Guava flow cytometers expand our core instrument offerings, adding cost-effective, entry-level and personal instrument options with microcapillary-based fluidics for cell analysis.
Our worldwide commercial team of more than 270 employees and our research and development team of more than 150 employees have significant expertise, industry experience and collaborative relationships with key opinion leaders ( KOLs ), industry leaders, innovators and potential customers.
We believe our financial results reflect the continued market demand for our product offerings and adoption of our FSP technology: our strong financial profile is differentiated by the combination of our scaled revenue base, revenue growth and cash balance.
+7 more — sign up free →
REMOVED
commercial launch in mid-2017 through December 31, 2024, we have sold and deployed our instruments to customers around the world, including pharmaceutical companies, biopharma companies, academic research centers, and clinical research organizations ( CROs ).
Flow Cytometry and Imaging (FCI) Business On February 28, 2023, we completed the acquisition of certain assets (the FCI Acquisition ) relating to the flow cytometry and imaging business of Luminex Corporation ( Luminex ), including relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis - and Guava -branded instruments, and flow cytometry reagent products and services (the FCI Business ).
The acquired FCI Business includes conventional flow and image-based flow cytometry instrumentation and related products and services (the FCI Products ), which provide insights into all facets of cellular phenotypes and morphology.
The addition of Guava flow cytometers expands our core instrument offerings, adding cost-effective, entry-level and personal instrument options with microcapillary-based fluidics for cell analysis.
The FCI Acquisition supports our plan to develop new products and capabilities with flow cytometry and imaging technology, expand our reach and offerings into customer segments previously underserved, and increase the efficiency of our operations .
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →